The effects of statin monotherapy and low-dose statin/ezetimibe on lipoprotein-associated phospholipase A2

Clinical Cardiology

Volumn 34, Issue 2, 2011, Pages 108-112

  Lee, Sang Hak ^a   Kang, Seok Min ^a   Park, Sungha ^a   Jang, Yangsoo ^a   Chung, Namsik ^a   Choi, Donghoon ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BIOLOGICAL MARKER; EZETIMIBE; FIBRINOGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCYTE CHEMOTACTIC PROTEIN 1; PHOSPHOLIPASE A2;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; DRUG EFFECT; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; LIPID BLOOD LEVEL; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MYALGIA; PLEIOTROPY; RANDOMIZED CONTROLLED TRIAL; THROMBOSIS;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADULT; AGED; ANTICHOLESTEREMIC AGENTS; AZETIDINES; BIOMARKERS, PHARMACOLOGICAL; CHEMOKINE CCL2; CHOLESTEROL, LDL; DRUG THERAPY, COMBINATION; FEMALE; FIBRINOGEN; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; INTERLEUKIN-6; MALE; MIDDLE AGED; PYRROLES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79751486106     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.20853     Document Type: Article

References (20)

1. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994; 344: 1383-1389.
2. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995; 333: 1301-1307.
3. Ridker PM, Cannon CP, Morrow D, et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005; 352: 20-28. (Pubitemid 40075677)
4. Saougos VG, Tambaki AP, Kalogirou M, et al. Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2. Arterioscler Thromb Vasc Biol. 2007; 27: 2236-2243. (Pubitemid 350287255)
5. Laufs U, La Fata V, Plutzky J, et al. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 1998; 97: 1129-1135. (Pubitemid 28152885)
6. Alber HF, Dulak J, Frick M, et al. Atorvastatin decreases vascular endothelial growth factor in patients with coronary artery disease. J Am Coll Cardiol. 2002; 39: 1951-1955. (Pubitemid 34628275)
7. Cipollone F, Mezzetti A, Porreca E, et al. Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: effects of statin therapy. Circulation. 2002; 106: 399-402. (Pubitemid 34803680)
8. Piorkowski M, Fischer S, Stellbaum C, et al. Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone. J Am Coll Cardiol. 2007; 49: 1035-1042.
9. Liu PY, Liu YW, Lin LJ, et al. Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on Rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation. Circulation. 2009; 119: 131-138.
10. 2 in patients with coronary heart disease versus control subjects. Am J Cardiol. 2005; 95: 1025-1032. (Pubitemid 40544302)
11. Pearson TA, Ballantyne CM, Veltri E, et al. Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy. Am J Cardiol. 2009; 103: 369-374.
12. Her AY, Kim JY, Kang SM, et al. Effects of atorvastatin 20 mg, rosuvastatin 10 mg, and atorvastatin/ezetimibe 5 mg/5 mg on lipoproteins and glucose metabolism. J Cardiovasc Pharmacol Ther. 2010; 15: 167-174.
13. Ballantyne CM, Houri J, Notarbartolo A, et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation. 2003; 107: 2409-2415. (Pubitemid 36605221)
14. Mäki-Petäjä KM, Booth AD, Hall FC, et al. Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis. J Am Coll Cardiol. 2007; 50: 852-858. (Pubitemid 47268750)
15. Ky B, Burke A, Tsimikas S, et al. The influence of pravastatin and atorvastatin on markers of oxidative stress in hypercholesterolemic humans. J Am Coll Cardiol. 2008; 51: 1653-1662. (Pubitemid 351626406)
16. De Lemos JA, Morrow DA, Blazing MA, et al. Serial measurement of monocyte chemoattractant protein-1 after acute coronary syndrome. J Am Coll Cardiol. 2007; 50: 2117-2124. (Pubitemid 350117348)
17. Hanefeld M, Marx N, Pfützner A, et al. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study. J Am Coll Cardiol. 2007; 49: 290-297. (Pubitemid 46110954)
18. Rallidis LS, Hamodraka ES, Fountoulaki K, et al. Simvastatin exerts its anti-inflammatory effect in hypercholesterolaemic patients by decreasing the serum levels of monocyte chemoattractant protein-1. Int J Cardiol. 2008; 124: 271-272. (Pubitemid 351173361)
19. Pitsavos C, Skoumas I, Tousoulis D, et al. The impact of ezetimibe and high-dose statin treatment on LDL levels in patients with heterozygous familial hypercholesterolemia. Int J Cardiol. 2009; 134: 280-281.
20. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* trial). Am J Cardiol. 2003; 92: 152-160. (Pubitemid 36835963)